DWTX Stock Overview
A development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
My Notes
Capture your thoughts, links and company narrative
Dogwood Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.87 |
| 52 Week High | US$23.50 |
| 52 Week Low | US$1.62 |
| Beta | 1.33 |
| 1 Month Change | 12.55% |
| 3 Month Change | -34.29% |
| 1 Year Change | -80.15% |
| 3 Year Change | -97.78% |
| 5 Year Change | n/a |
| Change since IPO | -99.31% |
Recent News & Updates
Recent updates
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Aug 24
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?
May 11Virios Therapeutics slides 11% postmarket on proposed stock offering
Sep 19Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07
Aug 11Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jun 25Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Mar 09Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?
Nov 02Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jul 19Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study
Jun 04Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans
Mar 31Virios Therapeutics gains 10% on research deal in irritable bowel syndrome
Feb 01Virios Therapeutics prices IPO at $10
Dec 17Shareholder Returns
| DWTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.6% | -3.3% | -0.4% |
| 1Y | -80.1% | -2.7% | 24.8% |
Return vs Industry: DWTX underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: DWTX underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| DWTX volatility | |
|---|---|
| DWTX Average Weekly Movement | 26.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DWTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DWTX's weekly volatility has increased from 21% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 4 | Greg Duncan | www.dwtx.com |
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
Dogwood Therapeutics, Inc. Fundamentals Summary
| DWTX fundamental statistics | |
|---|---|
| Market cap | US$3.82m |
| Earnings (TTM) | -US$5.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs DWTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DWTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.73m |
| Earnings | -US$5.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DWTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 13:09 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dogwood Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lee | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| David Bautz | Zacks Small-Cap Research |